Labcorp Stock Quote and Financial Performance Overview

Labcorp is a leading global life sciences company that provides clinical laboratory testing and services.

The company has a market capitalization of over $40 billion, indicating its significant size and influence in the industry.

Labcorp's revenue has consistently grown over the years, with a total revenue of $14.5 billion in 2020.

The company's financial performance is a key factor in determining its stock price, with investors closely monitoring its quarterly earnings reports.

Labcorp's revenue in 2023 was $12.16 billion, a 2.51% increase from the previous year. This growth is a positive sign for the company.

Their earnings, however, took a hit, decreasing by -67.32% to $418.00 million. Despite this, Labcorp still managed to beat Wall Street estimates for third-quarter profit and revenue.

Labcorp's financial performance is expected to continue growing, with estimated revenue reaching $13,812 million in 2025 and $14,506 million in 2026. Here's a breakdown of their estimated revenue and earnings per share (EPS) for the next few years:

Labcorp's average earnings estimates for the current quarter ending 03/31/25 is $3.869 USD, while the average revenue estimate is $3,414 USD.

Estimates in USD are a crucial aspect of financial information. Labcorp Holdings has provided estimates for the years 2025, 2026, 2027, and 2028.

Revenue estimates for Labcorp Holdings are as follows: $13,812 million in 2025, $14,506 million in 2026, $15,570 million in 2027, and $16,455 million in 2028.

The average number of analysts estimating Labcorp's revenue is 15 in 2025 and 13 in 2026. The average estimate for revenue in 2025 is $14,506 million, with an average estimate of $14,506 million in 2026.

Labcorp's earnings per share (EPS) are expected to be $16.04 in 2025, $17.61 in 2026, $19.67 in 2027, and $21.60 in 2028. The EPS (Non-GAAP) ex. SOE is expected to be $14.34 in 2025 and $15.67 in 2026.

The P/E ratio is expected to decrease over the next few years: 15.57 in 2025, 14.18 in 2026, 12.69 in 2027, and 11.56 in 2028.

Here is a summary of the estimates in USD:

Note: The average number of analysts and average EPS estimates are not available for 2027 and 2028.

Labcorp has a history of paying dividends to its shareholders, with a current dividend yield of 1.20% and 1.23% for the years 2025 and 2026, respectively.

The company's dividend payment is $3.00 per share for 2025 and $3.07 per share for 2026.

Labcorp's dividend yield has been increasing over the years, from 1.27% in 2023 to 1.20% in 2025.

Here's a breakdown of Labcorp's dividend payments and yields over the years:

Labcorp's dividend payment is a quarterly dividend of $0.72 per share, as mentioned in a recent article.

Labcorp's revenue in 2023 was $12.16 billion, a 2.51% increase from the previous year. This growth is a positive sign for investors.

Labcorp's current share price is $249.67, which is a significant jump from its 52-week low of $191.97. The company's stock has been on a roll, with a 1-month change of 8.35% and a 3-month change of 9.46%.

In terms of financial health, Labcorp's earnings in 2023 were $418 million, but this was a decrease of 67.32% from the previous year. This decline in earnings is a concern for investors.

Here's a summary of Labcorp's stock performance over the past year:

Labcorp's stock has been beating expectations, including a recent quarter where the company beat Wall Street estimates for profit and revenue. This strong performance has helped boost the company's stock price.

Labcorp has received a conditional approval from Italian authorities to sell a 15% stake in Synlab to laboratory operator Labcorp. This approval is a significant step forward for the company's plans.

Julia Wang has been named as the new Chief Financial Officer of Labcorp, starting from December 2, 2024.

Cinven has secured a conditional approval from Italian authorities to sell a 15% stake in Synlab to Labcorp. This move is a significant step forward for both companies.

The approval allows Cinven to proceed with the sale, pending any further conditions being met. Private equity firm Cinven has been working on this deal for some time.

Labcorp is a global leader in laboratory services, and this acquisition will strengthen its position in the market. It's a big win for the company.

The sale of the minority stake is expected to be completed soon, pending any final regulatory approvals.

CommonWell Health Alliance has added a new member to its ranks. Labcorp, a global leader in laboratory services, is now part of the alliance.

This is an exciting development for the healthcare industry, as Labcorp brings its expertise and resources to the table. Labcorp is known for its innovative and comprehensive laboratory services.

Labcorp's membership in CommonWell Health Alliance will likely have a positive impact on the industry. It's great to see companies like Labcorp working together to improve healthcare.

By joining CommonWell Health Alliance, Labcorp will have access to new opportunities and partnerships. This can help Labcorp expand its services and reach new customers.

Labcorp is a global leader in its field, and its membership in CommonWell Health Alliance is a testament to its commitment to innovation and collaboration.

Consider reading: Stock Quote New York Community Bank

Labcorp has completed the acquisition of select assets of BioReference Health's diagnostics business from OPKO Health. This move enhances Labcorp's laboratory services network.

The acquisition expands access to Labcorp's clinical services, which is a significant development for the company.

Labcorp offers a quarterly dividend, with a current payout of $0.72 per share. This is a great opportunity for investors to earn a steady income from their investment.

The dividend yield is 1.27% as of 2023, which is a relatively modest return compared to other investment options. However, it's still a decent addition to an investor's portfolio.

Here's a breakdown of Labcorp's dividend history:

Note that Labcorp did not pay a dividend in 2021 or earlier years.

Labcorp Holdings has received analyst opinions from various firms. The average rating for LH stock is "Buy" according to 16 analysts.

Analysts have provided specific price forecasts for Labcorp Holdings. The 12-month stock price forecast is $261.21, which represents a 5.07% increase from the latest price.

Labcorp Holdings has received specific ratings from analysts. On July 9, 2024, Evercore maintained a "Hold" rating with a price target of $215.

Here is a summary of analyst opinions for Labcorp Holdings:

Labcorp Holdings has received positive ratings from analysts. On July 8, 2024, Baird Patrick & Co maintained a "Buy" rating with a price target of $261.

Labcorp's dividend history shows a steady increase over the years. The company has declared a quarterly dividend of $0.72/share.

According to Labcorp's dividend calendar, the company has been paying dividends since at least 2012. The dividend payout has been consistent, with no dividends paid out in 2021 and 2020.

Here is a breakdown of Labcorp's dividend history: